Opthalmology
Five Responder Subgroups, Hidden in Plain Sight
.avif)
Challenge
A Phase II randomized, double-blind, six-arm trial evaluated FOV 1101 in combination with another therapeutic agent for patients with persistent allergic conjunctivitis. Across the full study population of 724 patients, only two efficacy endpoints reached statistical significance — leaving the therapeutic potential of FOV 1101 unclear.
Approach
KEM® analyzed clinical and biomarker data from all 724 patients, characterized by 165 patient descriptors across 12 predefined efficacy endpoints. Using association-rule mining, KEM® explored the complex interactions between patient characteristics and clinical outcomes to identify biologically meaningful responder subgroups within the larger population.
KEM® identified five clinically actionable, biomarker-defined responder subgroups - narrow populations within the larger 724-patient trial who showed markedly improved treatment response. Within these subgroups, KEM® uncovered 37 significant efficacy endpoints, compared with just two across the unstratified population. These findings played an important role in the discussions preceding Sanofi's acquisition of Fovea Pharmaceuticals.
In October 2009, Sanofi announced the acquisition of Fovea Pharmaceuticals for up to €370 million, including milestone payments. Sanofi's official announcement highlighted FOV 1101 and Fovea's ophthalmology pipeline as strategic assets supporting the deal. According to Pierre Belichard, Fovea's former COO, Ariana's analyses were "instrumental in the outcome of discussions" during the M&A process.